NCT02210819 - Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy | Biotech Hunter

Enrollment

1,987

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

November 3, 2016

Study Completion Date

January 20, 2017

Conditions

Deep Vein Thrombosis (DVT)Pulmonary Embolism (PE)

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"

DRUG

Recommended VTE pharmacological treatments according to international guidelines

"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."

Trial Locations (21)

Unknown

Multiple Locations